The FDA approved Gilead's twice-yearly injectable lenacapavir for HIV prevention. It adds an option that may help people who struggle with daily pills, though the report gives no sales or patient-use figures.
A dose every 6 months may help people who struggle with daily pills. The article says the treatment also aims to reduce stigma. It gives no sales or patient-use figures, so the size of the business benefit is not yet known.
Follow Gilead Sciences (GILD) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for GILD